Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference

Rhea-AI Summary

Trevena, Inc. (Nasdaq:TRVN) announced its participation in the H.C. Wainwright Annual Global Investment Conference from September 12-14, 2022, in New York. The company's corporate overview presentation is scheduled for September 12 at 4:30 PM ET. A webcast link will be available on Trevena's investor website, with a replay accessible for 30 days post-event. Trevena focuses on developing innovative medicines for CNS disorders, with an approved product, OLINVYK, for acute pain management, and a promising pipeline that includes candidates for diabetic neuropathic pain, migraine, and opioid use disorder.

CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in-person and virtually September 12- 14, 2022, in New York.

Presentation Details
Date: Monday, September 12, 2022
Time: 4:30pm ET
Webcast Link

A link to the webcast will be available on the Events page of the Investors section of the Company’s website at https://www.trevena.com/investors/events-presentations/ir-calendar   

A replay of the presentation will be archived on the website and available for approximately 30 days following the event. Please contact your H.C. Wainwright representative to schedule one-on-one meetings with Trevena during the conference.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK^® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

For more information, please visit www.Trevena.com

For more information, please contact:

Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576

PR & Media Contact:

Sasha Bennett
Associate Vice President
Clyde Group
Sasha.Bennett@clydegroup.com
(239) 248-3409

Company Contact:

Bob Yoder
SVP and Chief Business Officer
Trevena, Inc.
(610) 354-8840

FAQ

When is Trevena's presentation at the H.C. Wainwright Annual Global Investment Conference?

Trevena's presentation is scheduled for September 12, 2022, at 4:30 PM ET.

Where can I watch Trevena's presentation webcast?

The webcast link for Trevena's presentation will be available on their investor website.

What is Trevena's focus in biopharmaceuticals?

Trevena focuses on developing innovative medicines for patients with central nervous system (CNS) disorders.

What products does Trevena have in its pipeline?

Trevena's pipeline includes TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for migraine treatment, and TRV734 for opioid use disorder.

What is OLINVYK and how is it used?

OLINVYK (oliceridine) is Trevena's approved product for managing acute pain in adults requiring intravenous opioid analgesics.